Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation, titled “Tissue Concentration–Driven Toxicology of Everolimus: Implications for Nanoparticle Delivery,” will highlight findings that go beyond traditional plasma pharmacokinetics to examine organ-specific outcomes based on tissue-level drug distribution.
According to the company, the research underscores the importance of understanding where the drug accumulates in the body to predict and mitigate toxicity. By focusing on tissue concentration–driven effects, the study aims to inform the development of improved delivery strategies, including intravenous administration and nanoparticle-based formulations. These approaches could potentially enhance the therapeutic index of everolimus, a drug used in oncology, by reducing off-target effects while maintaining efficacy.
“This work represents a significant step in nanomedicine, as it demonstrates that tissue distribution, not just plasma levels, dictates toxicity profiles,” said a company spokesperson. “Our findings support the use of advanced delivery systems to achieve more precise drug localization.”
Sapu Nano, a wholly owned subsidiary of Oncotelic, focuses on developing next-generation nanomedicine platforms to improve drug delivery and unlock new clinical potential for both established and novel therapeutics, primarily in oncology. The company’s research aligns with broader trends in the field, where nanoparticle carriers are being designed to alter biodistribution and reduce systemic side effects.
The Society of Toxicology meeting, scheduled for March 2026, will provide a platform for Sapu Nano to present its data to a global audience of toxicologists and pharmaceutical scientists. The full press release detailing the announcement can be accessed here.
Oncotelic Therapeutics, formerly known as Mateon Therapeutics, is a biotechnology company focused on oncology drug development, with a special emphasis on rare pediatric cancers. The company holds rare pediatric disease designations for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture, GMP Bio, as well as for melanoma and acute myeloid leukemia. Additionally, Oncotelic has expanded into neurodegenerative diseases through its acquisition of AL-101 for intranasal apomorphine delivery, targeting conditions such as Parkinson’s disease.
The upcoming presentation at SOT 2026 is expected to generate interest among researchers and investors alike, as it highlights a mechanistic approach to improving drug safety. For more information on Oncotelic and its subsidiaries, visit the company’s newsroom here.
